AstraZeneca and Daiichi Sankyo's Breast Cancer Drug Approved for NHS Use in England
England’s National Health Service (NHS) has approved AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo’s breast cancer drug Enhertu for patients with HER2-low metastatic breast cancer, reversing a prior rejection by the UK's health technology assessment body NICE. The decision followed changes in valuation methods and a U.S.-UK pricing agreement aimed at aligning medicine prices. Approximately 1,000 women per year are expected to benefit from NHS coverage. Enhertu is already a significant growth driver for AstraZeneca, with combined sales reaching $2.96 billion in the first half of 2026—a 29% increase compared to last year. The drug’s approval expands access within one of Europe's largest healthcare markets and supports broader geographic adoption across multiple indications. However, financial benefits from NHS coverage may be limited due to low patient numbers and undisclosed pricing terms agreed with NICE. While the decision is strategically positive for AstraZeneca, it represents a relatively small incremental opportunity compared to Enhertu’s already strong revenue performance.
Tickers: $AZN
Topics: breast cancer treatment healthcare policy NHS approval pharmaceuticals